

AUTHOR CORRECTION

Open Access

Correction: Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma

Mohamed Houseni¹, Mahmoud Abdel Aziz Abdel Hady¹ and Sameh Abokoura^{1*}

Correction: Egypt Liver Journal 13, 41 (2023) https://doi.org/10.1186/s43066-023-00276-6

Following publication of the original article [1], the abstract and keywords were missing from this article and should have read:

Abstract

Objective: This study's purpose was to evaluate the response, safety and overall survival of trans-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with preserved hepatic function.

Methods: This study was carried out on 25 patients, diagnosed with hepatocellular carcinoma (HCC) combined with portal vein tumor thrombosis (PVTT) and underwent hepatic artery infusion chemotherapy (HAIC). Radiological investigations as Triphasic CT or dynamic MRI liver assessment pre and post therapy were acquired. Intra-Arterial chemotherapeutic agent infusion using only doxorubicin was performed.

Results: Neither of the patients who underwent HAIC developed complete or partial response. Only one patient (4.8%) from 21 patients under HAIC had stable disease. 20 patients (95%) had progressive disease. Progressive disease was in form of progression at the primary tumor site in form of increased focal lesion

The original article can be found online at https://doi.org/10.1186/s43066-023-00276-6.

*Correspondence:

Sameh Abokoura

samehabokoura@gmail.com

¹ Department of Radiology, National Liver Institute, Menoufia University, Shebin Elkoum, Egypt size, number or vascular invasion. Vascular invasion was seen in one patient (4.8%) in the form of hepatic vein thrombosis. Mean progression free survival was about 2.24 ± 0.88 months. Mean overall survival was about 5.72 ± 0.89 months.

Conclusion: Our study demonstrated lower clinical efficacy and lower disease control rate of repeated HAIC using doxorubicin only infusion in case of advanced HCC with PVT as compared to combined doxorubicin and cisplatin in previous studies as well as the standard therapy with sorafenib.

Keywords

Hepatic artery infusion chemotherapy, Portal vein tumor thrombosis, Advanced hepatocellular carcinoma The original article [1] has been updated.

Published online: 18 December 2023

Reference

 Houseni M, Hady MAAA, Abokoura S (2023) Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. Egypt Liver J 13:41. https://doi.org/10.1186/s43066-023-00276-6



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.